Table 3.

Summary of studies that evaluated the prognostic value of BNP and NT-pro-BNP in ESRDa

AuthorPatientsFollow-upNo. of EventsOutcome and HR (95% CI)
Studies using BNP
    Zoccali et al.,38 2000212 HD and 34 PD26 ± 10 mo63 deaths, 74 CV eventsDeath: HR 1.62 (1.20 to 2.17), P = 0.001 for 1-unit increase in log-BNP
CV death, T3 versus T1: HR 6.72 (2.44 to 18.54), P = 0.0002
    Cataliotti et al.,37 2001112 HD26 ± 10 mo16 CV deathsCV death: HR 2.18 (1.26–3.76), P = 0.005 for 1-unit increase in log-BNP
    Naganuma et al.,39 2002164 HD36 mo13 cardiac deathsCardiac death, Q4 versus Q1: HR 51.9 (6.5 to 416.3)
    Goto et al.,50 200253 HD11.3 ± 0.3 mo13 CV eventsCV events: HR not given (P < 0.0001)
    Rutten et al.,51 200668 PDAt least 18 mo10 deathsDeath, BNP > median: HR 8.5 (1.0 to 73.8), P = 0.05
Studies using NT-pro-BNP
    Apple et al.,31 2004399 HD24 mo101 deathsDeath, upper tertile: NT-pro-BNP >18,692 pg/ml increased mortality
    Wang et al.,35 2007240 PD36 mo66 deaths, 87 circulatory congestion, 43 CV deaths, 78 CV eventsDeath, Q4 versus Q1: HR 4.97 (1.35 to 18.28), P = 0.016
Circulatory congestion, Q4 versus Q1: HR 4.25 (1.56 to 11.62), P = 0.005
CV death – Q4 versus Q1: HR, 7.50 (1.36 to 41.39), P = 0.021
CV events, Q4 versus Q1: HR 9.10 (2.46 to 33.67), P = 0.001
    Madsen et al.,32 2007190 HD24 mo34 deathsDeath, pre-HD log-NT-pro-BNP: HR 1.42 (1.10 to 1.82), P = 0.007
Death, post-HD log-NT-pro-BNP: HR 1.52 (1.18 to 1.96), P = 0.001
    Sommerer et al.,52 2007134 HD36 mo74 deaths and CV eventsDeath and CV events: HR 3.2 (1.70 to 6.02), P < 0.001
    Satyan et al.,34 2007150 HD24 mo46 deaths, 26 CV deathsDeath, Q4 versus Q1: HR 4.03 (1.31 to 12.40), P = 0.02
CV death: HR 8.54 (1.04 to 69.98), P = 0.05
    Sharma et al.,53 200750 HD and 29 PD2.25 ± 0.71 yr21 deathsDeath: HR 5.57 (3.14 to 8.21), P = 0.02 (univariate analysis)
  • a CI, confidence interval; CV, cardiovascular; HR, hazard ratio; Q, quartile; T, tertile.